SABCS Program Director Kate Lathrop, MD, talks with Shom Goel, MBBS, PhD, about CDK4/6 inhibitors and emerging options to advance treatment for HR-positive, HER-negative metastatic breast cancer.
▷ Estimated Read Time:
1–2 minutes
SABCS Snippets: Beyond CDK4/6 Inhibitors
Connect with thousands of basic and translational scientists, multidisciplinary clinicians, regulatory and pharmaceutical partners, survivors, and patient advocates at the 49th annual San Antonio Breast Cancer Symposium. Complete your registration by Friday, September 25, to take advantage of discounted early registration rates.
Share: